יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Sunshine Biopharma (SBFM)

Sunshine Biopharma (SBFM) is developing innovative methods to combat tumors and viruses, with the creation of mRNA therapies and the sale of licenses to pharma behemoths serving as the key drivers. The operating model is based on outsourcing production in North America, which minimizes capital expenditures. However, limited capital and early-stage testing weaken patent protection. This price chart with the 0.00 metric confirms the current fundamental state of the business.

The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before depreciation, taxes, and interest. By analyzing the EV/EBITDA valuation ratio over time, an investor determines the asset's payback period while accounting for the debt load. For Sunshine Biopharma (SBFM), this indicator highlights the absence of current operating profit, as the development of anti-tumor drugs is fully funded by external capital.